Omnio, a Swedish biotech startup based in Umeå, has raised €2.9 million ($3.1 million) in an oversubscribed financing round led by existing investors and shareholders. The capital injection represents a significant milestone for the company as it accelerates development of its plasminogen-based biologic therapy targeting chronic wounds, including diabetic foot ulcers.
This latest round brings Omnio’s total funding to €7.2 million following an earlier €4.3 million Series A round in 2025. The company plans to deploy the fresh capital across several critical development stages, including scaling up manufacturing capabilities to Good Manufacturing Practice (GMP) standards, conducting necessary toxicology studies, and preparing for its first Phase I/IIa clinical trials.
Advancing Toward Human Studies
Chronic wounds represent a significant healthcare challenge in Europe and globally, particularly among patients with diabetes and other conditions affecting wound healing. Omnio’s plasminogen-based therapeutic approach addresses a substantial unmet medical need in this patient population. The company’s focus on moving from preclinical research into early-stage clinical development marks a pivotal transition in its corporate trajectory.
Felipe Velasquez, speaking on behalf of the company, emphasized the strategic importance of the funding round: “This financing demonstrates our continuous progress and strong confidence from our current investors. Their support allows us to continue the development and puts us in a stronger position ahead of our next financing round for clinical studies.”
The statement reflects investor confidence in Omnio’s scientific approach and development strategy. The company has already outlined its path forward, with plans for an additional financing round scheduled for 2027 to support the progression through clinical trials and regulatory approval processes.
Building Momentum in European Biotech
Omnio’s funding success illustrates the continued viability of European biotech innovation, particularly within specialized therapeutic areas. Swedish biotech has established itself as a notable contributor to the continent’s life sciences ecosystem, with multiple companies pursuing advanced therapeutics in areas ranging from wound care to rare diseases.
The oversubscribed nature of this round—indicating demand from investors exceeding the capital available—suggests strong market perception of both Omnio’s technology and its commercial potential. This type of investor appetite provides the company with negotiating leverage and validates its scientific direction.
The pathway Omnio has outlined reflects the typical capital requirements for biotech companies transitioning from laboratory research to clinical validation. Manufacturing scale-up and toxicology work are essential prerequisites for regulatory submissions seeking approval to test investigational therapies in human patients, making these investments critical stepping stones toward eventual commercialization.
As European regulatory agencies continue to support innovative therapeutic development, companies like Omnio exemplify the region’s ongoing commitment to advancing next-generation treatments for conditions affecting millions of patients.